University of Patras GR-26504 Patras. Country: GREECE to Laboratoire de Chimie de Coordination du CNRS - UPR8241 Inserm ERL 1289 Équipe “Nouvelles molécules antipaludiques et approches pharmacologiques” 205 route de Narbonne - BP 44099 - 31077 Toulouse Cedex, France

A family of naturally occurring endoperoxides called G-factors (G1-G3), is developed by the team. They are structurally six-membered unsaturated cyclic endoperoxides fused to another six-carbon ring deriving from syncarpic acid. They are endogenous in the leaves of Eucalyptus grandis and some other myrtaceous plants. Two synthetic methodologies have already been elaborated and optimized, one giving access to carbon labelled derivatives. Our work concerning the antimalarial activity of the families synthetized indicated that: a) while G3 compound was very poorly active against P. falciparum (36µM), the G3Me presented a very interesting antimalarial activity (280nM), b) R1(or R2) and R positions when alkylated afforded compounds with very potent antiplasmodial activities c) hybrid highly potent molecules were synthetized (IC50 = 13nM and 31nM for chloroquine resistant W2 strain and 3D7 chloroquine susceptible strain); d) our first preliminary results (chemical spectroscopic means) indicated no alkylation, contrary to artemisinin, when reacting G3Me with Mn-porphyrin system, indicating that  these new antimalarial candidates could be particularly promising.

The aim of the integral project can be resumed in five main points: 1a: elaborate G3 compounds bearing same type of terminal alkynes (or azides) functions either on the peroxy-hemiketal position or on the lateral chain; 1b: construct focalized libraries for SAR studies, each compound bearing the alkyne (or azide) fragment. 2 and 3: in vitro activity and cytotoxicity evaluation of all compounds against P. falciparum wild and resistant strains. 4:Construct hybrids with other antimalarial pharmacophores, particularly with plasmodione, menadione and HDAC derivatives through click chemistry approaches. 5: Select the 4 most potent derivatives and synthetize them in their labelled forms. 6: Undertake in vitro and in vivo studies for elucidating the mechanism of action of two of the most promising compounds where a coumarin-based fluorescent probe will be also installed.

Finally, chemoproteomics and large-scale quantitative proteomics strategies studies will be performed using adequate Plasmodium parasites cell lines as cellular contexts. 

COST
What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

OneHealthdrugs CA21111
Title:

One Health drugs against parasitic vector borne diseases in Europe and beyond

Acronym:

OneHealthdrugs

Start date of the Action:

24/10/2022

End date of the Action:

23/10/2026

CSO approval date:

27/05/2022

Memorandum of Understanding (MoU)

Download file

Contact Points
Chair:

Maria Paola Costi

Vice-Chair:

Anabela Cordeiro da Silva

COST staff

Scientific Officer:
Wioleta Walentowska
Administrative Officer:
Nathalie Warenghien

Administrative Team

Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi